Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 26 June 2024 - 16:30

Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-939

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters